Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9UNE7

UPID:
CHIP_HUMAN

ALTERNATIVE NAMES:
Antigen NY-CO-7; CLL-associated antigen KW-8; Carboxy terminus of Hsp70-interacting protein; RING-type E3 ubiquitin transferase CHIP; STIP1 homology and U box-containing protein 1

ALTERNATIVE UPACC:
Q9UNE7; A2IDB9; O60526; Q969U2; Q9HBT1

BACKGROUND:
The E3 ubiquitin-protein ligase CHIP, known for its roles as a co-chaperone and ubiquitin ligase, is crucial in the degradation of misfolded proteins and regulation of protein quality. By targeting various substrates, including NOS1, POLB, and CYP3A4 for ubiquitination, CHIP ensures cellular proteostasis and regulates key physiological processes.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in neurodegenerative disorders such as Spinocerebellar ataxia, autosomal recessive, 16 and Spinocerebellar ataxia 48, E3 ubiquitin-protein ligase CHIP represents a promising target for drug discovery. Its role in disease pathogenesis underscores the therapeutic potential of modulating CHIP activity.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.